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Value of anti-plasminogen binding peptide, anti-
carbonic anhydrase II, immunoglobulin G4, and
other serological markers for the differentiation of
autoimmune pancreatitis and pancreatic cancer
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∗
, Jesper D. de Vos, MDd,c, Julia T. Tanassi, DipEnge,
Niels H. H. Heegaard, MD, DMSce,f, Claus Fristrup, MD, PhDg,b,
Ove B. Schaffalitzky de Muckadell, MD, DMScd,c
Abstract
The diagnosis of autoimmune pancreatitis (AIP) and its differential diagnosis from pancreatic cancer (PC) can be challenging. In this
retrospective study, we aimed to evaluate the value of anti-plasminogen binding peptide (a-PBP), immunoglobulin G4 (IgG4), and
anti-carbonic anhydrase-II (a-CA-II), together with other serological markers whose value is not fully elucidated.
The serum levels of a-PBP, IgG4, IgG, anti-nuclear antibodies (ANA), anti-lactoferrin (a-LF), a-CA-II, and rheumatoid factor (RF)
were evaluated in patients with AIP (n=29), PC (n=17), pancreatic neuroendocrine neoplasm (P-NEN, n=12), and alcoholic chronic
pancreatitis (ACP, n=41). ANCA were measured in the AIP patients.
There was no statistically signiﬁcant difference in mean a-PBP values in AIP compared with PC. A ROC curve showed that, when
using a cut-off of 38.3U, low values of a-PBP had a sensitivity and speciﬁcity of 45% and 71% for differentiating AIP from PC. The
sensitivity and speciﬁcity of IgG4 (cut-off 1.4g/L) for differentiating AIP from PC was 45% and 88%, but rose to 52% and 88% when
using a cut-off of 1.09g/L. When using this cut-off, the sensitivity and speciﬁcity for differentiating type 1 AIP from PC was 68% and
88%. None of the other markers were signiﬁcantly changed in AIP versus PC. For differentiation of type 1 and type 2 AIP, the only
signiﬁcant differences were IgG4 in type 1 AIP (P< .01), with a sensitivity of 68% and a speciﬁcity of 80%, and c-ANCA elevations
found in some type 2 AIP patients (P< .05).
The only serological marker for which we found a statistically signiﬁcant difference in mean values between AIP and PC was IgG4.
However, the value of IgG4 for the distinction of AIP from PC was limited, probably in part due to the relatively high number of type 2
AIP patients in our study. In accord with recent publications, our data do not support a role of increased serum a-PBP for the
diagnosis of AIP.
Abbreviations: a-CA-II = anti-carbonic anhydrase II, ACP = alcoholic chronic pancreatitis, a-LF = anti-lactoferrin, ANA = anti-
nuclear antibodies, ANCA = anti-neutrophil cytoplasmic antibodies, a-PBP = anti-plasminogen binding peptide, AIP = autoimmune
pancreatitis, IgG = immunoglobulin G, IgG4 = immunoglobulin G4, IgG4-RD = IgG4-related disease, IgG4-SC = IgG4-related
sclerosing cholangitis, PC = pancreatic cancer, P-NEN = pancreatic neuroendocrine neoplasm, RF = rheumatoid factor.
Keywords: anti-neutrophil cytoplasmic antibodies, anti-carbonic anhydrase II, anti-lactoferrin, anti-plasminogen binding peptide,
autoimmune pancreatitis, immunoglobulin G4
1. Introduction
In 1995, Yoshida et al[1] were among the ﬁrst to describe
autoimmune pancreatitis (AIP) as a new entity of pancreatitis. They
characterized AIP as a chronic pancreatic disease showing
autoantibodies, diffuse enlargement of the pancreas, irregular
strictures of the main pancreatic duct, lymphoplasmacytic inﬁltra-
tion at histology, mild pancreas-related symptoms without any
acute attacks, and good response to corticosteroids. AIP is now
divided into two subtypes named type 1 and type 2 AIP, based on
histological, clinical, and serological features.[2–5] Regarding
clinical symptoms and imaging, both subtypes of AIP have a
signiﬁcant overlapwith pancreatic cancer (PC), whichmakes AIP a
relevant differential diagnosis of PC, despite its low incidence.[6]
Also alcoholic chronic pancreatitis (ACP) and pancreatic neuroen-
docrine neoplasms (P-NENs) can represent a differential diagnosis
in some instances. A pancreatic endoscopic ultrasound-guided ﬁne-
needle biopsy or a percutaneous core needle biopsy (CNB), an
invasive procedure not without risk of complications, is often
required for the diagnosis of AIP, especially when type 2 is
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considered.[7,8] van Heerde et al[9] found benign conditions in
approximately 8% of patients who had a pancreaticoduodenec-
tomy performed because of suspicion of PC, and around one-third
of these had AIP. Therefore, it is relevant to explore new methods
for diagnosing AIP and differentiating it from PC preoperatively,
particularly in geographical areas such as France orDenmark, with
a relatively high proportion of the IgG4-negative subtype of AIP
(type 2) and/or a relatively low sensitivity of serum IgG4 in type 1
AIP.[10,11] Different serological markers for the diagnosis of AIP
have been tested, but for now, the results are incoherent and
disappointing.[12–16] In the meta-analysis by Lian et al,[16]
sensitivity and speciﬁcity for IgG4 in differentiating AIP from PC
ranged from 52–95% to 81–99%. The present study intended to
revisit the usefulness of the serum markers anti-plasminogen
binding peptide antibodies (a-PBP), IgG4, IgG, anti-carbonic
anhydrase II antibodies (a-CA-II), anti-lactoferrin antibodies (a-
LF), anti-nuclear antibodies (ANA), and rheumatoid factor (RF)
for the differentiation of AIP from PC.[13,17] Besides, anti-
neutrophil cytoplasmic antibodies (ANCA) were measured in the
AIP patients.
2. Methods
The Regional Committees of Health Research Ethics of Southern
Denmark approved the study (project-ID: S-20150216). All
participants were enrolled after written and informed consent.
2.1. Participating patients
The study was conducted at Odense University Hospital (OUH).
Patients with AIP were included from the diagnostic registry at
OUH and the Danish Pathology Registry (Patobank) for the
period from 2005 to 2015. Twenty-two of the AIP patients were
included in a previous study.[11] Eligible patients had their
diagnosis established mainly by pancreatic core needle biopsy
(CNB) and/or imaging and their clinical course, based on a slight
modiﬁcation of the revised Histology, Imaging, Serology, Other
organ involvement and Response to steroid therapy (HISORt)
criteria of the Mayo Clinic for the diagnosis of AIP, as described
previously.[18] Even though endoscopic retrograde cholangio-
pancreatography (ERCP) is not part of the HISORt criteria, we
used diffuse or segmental narrowing of the main pancreatic duct
with irregular wall (more than 1/3 length of the entire pancreas)
without upstream dilatation of the main pancreatic duct as an
additional criterion to the HISORt criteria.[18] Importantly,
retrospectively, the included patients did fulﬁll the International
Consensus Diagnostic Criteria (ICDC) published in 2011.[19] If
pancreatic CNB was performed, the diagnosis was further
veriﬁed by using a previously published scoring system for the
diagnosis of AIP, consisting of 6 microscopic features.[20] Patients
with ACP (n=41), PC (n=17), and P-NEN (n=12) were
recruited from the outpatient clinic at the Department of
Gastroenterology, Odense University Hospital (OUH). The
diagnosis of PC (ductal adenocarcinoma) and P-NEN was based
on microscopy (ﬁne needle aspiration [FNA] cytology, CNB, or
resection specimen), imaging and follow-up (at least 6 months).
The diagnosis of ACP was based on clinical features and
morphological features (calciﬁcations and ductal changes) and/or
pancreatic functional insufﬁciency, according to theMultiple risk
factors, Alcohol, Nicotine, Nutrition, Hereditary, Efferent duct,
Immunological, Miscellaneous (M-ANNHEIM) criteria.[21]
None of the ACP patients fulﬁlled the above-mentioned criteria
for AIP. Serawere analyzed at the Statens Serum Institute (SSI) for
autoantibodies, serum IgG, and serum IgG4. Further, patient
records were scrutinized for follow-up data, recurrence of
disease, and other diseases connected to the primary condition,
AIP. If recorded data were found to be incomplete, the patient
was contacted for completion of the medical history.
2.2. Serological analysis
In this study, the cut-offs of the assays used were adjusted as the
mean values for healthy controls plus 2 to 3 times standard
deviation. All sera were stored at –80 °C until usage.
Anti-CA II antibodies (a-CA-II): ELISA procedures for serum
a-CA-II were carried out as described by Ono et al[22] with some
modiﬁcations. The 96-well microplate (NuncMaxisorp, Thermo
Scientiﬁc, Waltham, MA) was coated with 100mL of human CA-
II (Sigma, C6654, St. Louis, MO), 5mg/mL in carbonate–
bicarbonate buffer [pH 9.6] and incubated at 4 °C overnight. The
plate was blocked with 2% skimmed milk in phosphate buffered
solution (PBS) for 1hour at 37 °C. An anti-CA-II sample was used
to generate a standard curve consisting of seven calibrators (100,
50, 25, 12.5, 6.25, 3.125, and 1.56 units). All samples were
diluted in 0.2% skimmedmilk in PBS. After washing off unbound
materials, 100mL of diluted standard and samples were added in
duplicates into the appropriate wells, followed by incubation for
1hour at 37 °C. After washing the plate 3 times, 100mL of goat
anti-human IgG conjugated with alkaline phosphatase (AP)
(Sigma, A3188, 1:2000 dilution) was added to each well,
followed by incubation for 1hour at room temperature. The plate
was washed again three times and 100mL of freshly prepared 4-
nitrophenyl phosphate disodium salt hexahydrate (Sigma,
S0942) were added into each well, followed by incubation for
20minutes at room temperature. Enzyme activity was read at
405nm and 650nm as a reference in an ELISA reader
(VersaMax, Sunnyvale, CA). The absorbance value of each well
was compared and the concentrations for all samples were
calculated, using the 7-point standard curve and multiplied with
dilution factor to obtain the result in Units/mL.
Anti-PBP antibodies (a-PBP): An enzyme-linked immunosor-
bent assay (ELISA) for anti-PBP-peptide IgG antibodies was
performed. A microplate (Maxisorp) was coated with 100mL of
H-AKEERRY-OH (PBP, MW.951.01, Schafer-n, Copenhagen,
Denmark, 2mg/mL) in carbonate–bicarbonate buffer (dilution
1:100), pH 9.6, followed by incubation at 4 °C overnight. The
plate was washed three times with TTN buffer (0.05M Tris, 0.3
MNaCl, and 1%Tween 20, pH 7.5). A positive anti-PBP sample
(identiﬁed during screening at our laboratory) was used to
generate a standard curve consisting of 7 calibrators (100, 50, 25,
12.5, 6.25, 3.125, and 1.56 Units). All samples were diluted in
incubation buffer with 0.2% BSA and 100mL of each diluted
samples were added in duplicates into the appropriate wells,
followed by incubation for 1hour at room temperature. After
washing the plate 3 times with TTN buffer, 100mL of AP-
conjugated goat anti-human IgG (Sigma, A3188, 1:2000
dilutions) was added to each well and incubated for 1hour at
room temperature. The plate waswashed again 3 times with TTN
buffer, and 100mL of freshly prepared 4-nitrophenyl phosphate
disodium salt hexahydrate (Sigma) was added into each well,
followed by incubation for 20minutes at room temperature.
Enzyme activity was read at 405nm and 650nm as a reference, in
an ELISA reader (VersaMax). The absorbance value of each well
was compared and the concentrations for all samples were
calculated, using the 7-point standard curve and multiplied with
dilution factor to obtain the result in Units/mL.
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Anti-neutrophil cytoplasmic antibody (ANCA) screening:
The samples were diluted 1:10 in PBS and tested by indirect
immunoﬂuorescence technique, on ethanol and formalin-ﬁxed
human granulocytes, regarding the presence or absence of a
cytoplasmic (c-ANCA) or perinuclear (p-ANCA) immunoﬂuo-
rescence pattern.
Anti-lactoferrin antibodies were measured using an ANCA
Panel Kit (Wieslab, Lund, Sweden): The samples were diluted
1:80 in dilution buffer and incubated for 30minutes at room
temperature. The wells were then washed to remove unbound
antibodies and other components. A conjugate of AP-labeled
antibodies to human IgG (ready to use) was added to the wells
and incubated for 60minutes at room temperature. After a
further washing step, detection of speciﬁc anti-lactoferrin
antibodies was obtained by incubation with substrate solution.
The amount of bound antibodies correlated to the color intensity
and was measured at 405nm and 650nm as a reference in ELISA
reader (VersaMax). If the samples optical density (OD) value was
≥0.4, an OD-ratio was calculated using the formula
ODRatio ¼ ODvalue sample
ODvalue blank
An OD ratio<3 indicated that the sample was negative and an
OD ratio >3 that the sample was positive.
IgG and IgG4: All samples were measured using the BN
ProSpec system ([BNPS], Siemens, Erlangen, Germany), accord-
ing to the manufacturer‘s protocol. The concentrations for all
samples were calculated using the standard curve in BNPS to
obtain the results in g/L.
Anti-nuclear antibodies (ANA): ANA were determined using a
Hep-2 based indirect immunoﬂuorescence assay. The samples, a
positive control (+), a blank control (PBS), and a negative control
(–) were diluted at 1:160 in PBS. The diluted samples were
incubated onHep-2-slides (ANA 13 wells slides HEp-2 substrate,
Immuno Concepts, Sacramento, CA, cat no. SA2013) for 30
minutes at room temperature. After washing the slides 3 times for
10minutes in PBS, the slides were incubated with ﬂuorescein
isothiocyanate (FITC) Antibody Reagent (Immuno Concepts, cat
no. 2075CS, ready to use) for 30minutes. After washing the slides
3 times for 10minutes, they were evaluated using a ﬂuorescence
microscope. The identiﬁcation of ANA-positivity and its pattern
was based on a combination of the strength of the ﬂuorescent
signal and its location inside the Hep-2 cells.
Rheumatoid factor (RF): IgM RF were determined using an in-
house assay. Puriﬁed human IgG at 10mg/mL in carbonate buffer
(pH 9.6) was used (50mL/well) to coat the wells of a microtiter
plate under cover overnight at 4 °C. Wells were then blocked in
dilution buffer (200mL/well) overnight at 4 °C. Plates were
centrifuged dry and kept up to 6 months in the dark at –20 °C
before use. For the analysis, plates were washed 3 times for 1
minute in washing buffer and 50mL sera were applied to the wells
in duplicate at a dilution of 1:100 in dilution buffer. The
incubation included a 5-step dilution of an RF standard serum, a
negative control, a positive control, and a blank (buffer alone).
After incubation at room temperature for 1hour on a shaker, the
plate was washed for 3 times for 1 minute with washing buffer.
Afterwards, horse radish peroxidase (HRP)-conjugated rabbit
anti-human IgM (DAKO cat. no. P0215 [Agilent Technologies,
Santa Clara, CA) was added to the wells at a 1:9000 dilution.
After incubation for 1hour and another washing step, wells
were developed for HRP activity using o-phenylenediamine
dihydrochloride/H2O2. Color development was stopped after
approximately 15minutes using 150mL/well of 1M H2SO4.
Wells were read in an ELISA reader (Tecan Sunrise, Tecan,
Männedorf, Switzerland) at 492nm using 650nm as a reference.
U/mL values for the samples were ﬁnally calculated based on
absorbance values and extrapolation to the standard curve.
2.3. Statistical analysis
For comparison of continuous data between 2 groups the Mann–
WhitneyU test was used. For comparison of 3 groups, analysis of
variance (ANOVA) was used. Categorical data were compared
using the chi-squared-test between >2 groups and Fisher exact
test for 2 groups. A P value <.05 was considered statistically
signiﬁcant. ROC curve analysis was performed to evaluate the
markers as diagnostic tools. For the diagnostic performance,
95% conﬁdence intervals (CI) were calculated. STATA v. 15 was
used (StataCorp LLC, College Station, TX).
3. Results
3.1. Clinical aspects
Sera were obtained from patients diagnosed with AIP (n=29),
pancreatic cancer (PC) (n=17), pancreatic neuroendocrine
neoplasm (P-NEN, n=12), and ACP (n=41). The PC cohort
consisted of 8 men and 9 women, mean age 67 years (range: 54–
87 years). Five of the P-NEN patients were women and 7 were
men, with a mean age of 63 years (range: 40–79 years). The ACP
cohort included 30 men and 11 women, mean age 58 years
(range: 40–77 years). The AIP cohort consisted of 21 men and 8
women,mean age 56 years (range: 28–73 years). Themale/female
ratio was 3.75 in type 1 and 1.5 in type 2 AIP. Nineteen AIP
patients (65.5%)were diagnosed with type 1 AIP and 10 (34.5%)
with type 2. The majority of the diagnoses (n=25) were based on
histological HISORt criteria that included pancreatic core needle
biopsy (CNB) and/or pancreatic resection specimens (Table 1).
Four patients had the AIP diagnosis established without biopsy or
resection (Table 1). Four other patients (20% of type 1 AIP and
13.8% of all AIP) had a surgical procedure performed due to
suspicion of PC (Table 1). Histological examination showed the
microscopic features of type 1 AIP in these 4 patients. Type 1 AIP
patients were signiﬁcantly older than type 2 AIP (64.4 vs 40.9
years, P< .001, Table 2). The sex ratio showed a majority of men
in both groups, which was higher in type 1 AIP (not statistically
signiﬁcant). Type 1 AIP patients presented more often with
monosymptomatic jaundice when compared with type 2 (47% vs
20%, P= .23). Type 2 AIP patients signiﬁcantly more often
presented with acute pancreatitis (30% vs 0%, P= .03). We
Table 1
Type of tissue specimens contributing to the histological diagnosis
of 29 patients with autoimmune pancreatitis (AIP).
Procedure No. of AIP patients
Laparoscopic ultrasound-guided pancreatic
core needle biopsy (CNB)
13
Endoscopic ultrasound (EUS)-guided pancreatic
ﬁne needle biopsy (FNB)
2
Percutaneous pancreatic CNB 5
Whipple’s procedure 2
Left sided pancreatic resection 2
Liver CNB 1
No histology 4
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detected no other signiﬁcant differences regarding the clinical
debut symptoms.
As shown in Table 3, extrapancreatic manifestations of IgG4-
related disease (IgG4-RD) were found in 12 type 1 AIP patients
(63%) but none of type 2 AIP (P< .005). Of those with other
organ involvement (OOI) of IgG4-RD in type 1 AIP, IgG4-related
sclerosing cholangitis (IgG4-SC) was most frequent, although not
signiﬁcantly (P= .07). Two type 1 AIP patients (10.5%) had
involvement of 2 extrapancreatic organs. One type 1 AIP patient
who also was reported in our earlier study had involvement of 4
extrapancreatic organs, including IgG4-SC, lymphadenopathy,
perisplenitis, and lung disease.[11] Eight type 1 AIP patients
(42%) and 3 type 2 AIP patients (30%, P= .69) had other
autoimmune diseases. Inﬂammatory bowel disease (IBD, all
ulcerative colitis) was exclusively observed in type 2 AIP (30% vs
0%, P= .03). Extrapancreatic malignancy was found in 8 AIP
patients (all previous to the diagnosis of AIP, no currently active
disease). Six of these had type 1 AIP (31.5%) and 2 had type 2
(20%, P= .68). None of the AIP patients had hepatobiliary or
pancreatic malignancies.
3.2. Serological ﬁndings
Table 4 shows the average concentrations of the examined
serological markers. Serum IgG4 was signiﬁcantly higher in AIP
patients (mean 4.2g/L) and especially type 1 AIP patients (mean
6.0g/L) when compared with PC (mean 0.7g/L), P-NEN (mean
0.7g/L) and ACP (0.9g/L) (P< .01, ANOVA) (Table 4). The
sensitivity and speciﬁcity of IgG4 for differentiation of AIP from
PC/ACP was 45% and 84% (Table 5). The sensitivity and
speciﬁcity of IgG4 for differentiation of type 1 AIP from PC (or
PC/ACP) was 58% and 84% (Table 5). The sensitivity of IgG4
for differentiation of type 1 and type 2 AIP was 68% and 80%.
There was a lower mean a-PBP value in the AIP group
compared with the PC group, but this difference was not
statistically signiﬁcant (P= .1) (Table 4). However, we found a
signiﬁcant difference inmean a-PBP between the 3 groups, mainly
due to higher values in ACP (P= .01). Hence, our data do not
support that a-PBP antibodies are raised in AIP. RF were detected
slightly more frequently in PC patients compared with AIP, but
due to the low number of PC patients in whom this marker was
measured, no statistical analyses were performed. There was no
signiﬁcant difference detected between the groups with regard to
a-CA-II and ANA. The method of analysis for a-LF changed
during the study. As a result, serum values were determined for
11 ACP, 4 PC, 7 P-NEN, and 12 AIP (8 type 1) patients, whereas
categorical data (positive/negative) were determined for the
remaining patients. Anti-LF serum values showed no signiﬁcant
difference between the groups. Categorical a-LF values were
negative in the remaining patients.
Only markers with signiﬁcant different mean values between
the 3 groups (AIP, PC, and ACP) were used in the ROC curve
Table 2
Sex, age, and debut symptoms in type 1 and type 2 autoimmune
pancreatitis (AIP) patients.
Type 1 AIP
(n=19)
Type 2 AIP
(n=10) P-value
Sex, male/female (ratio) 15/4 (3.75) 6/4 (1.5) ns
Age, mean, years (SD) 64.4 (10.0) 40.9 (19.9) <.001
Debut symptoms (%)
Monosymptomatic jaundice 9 (47) 2 (20) ns
Jaundice together with
other symptoms
2 (10.5) 2 (20) ns
Pancreatic insufﬁciency 3 (16) 1 (10) ns
Random imaging ﬁnding 2 (10.5) 0 ns
Abdominal pain 4 (21) 4 (40) ns
Weight loss 1 (5) 3 (30) ns
Acute pancreatitis 0 3 (30) 0.03
ns=not signiﬁcant.
Table 3
Extrapancreatic organ involvement and occurrence of malignancy in type 1 and 2 autoimmune pancreatitis (AIP).
Type 1 AIP (n=19) Type 2 AIP (n=10) P-value
Organ involvement, IgG4-RD (%) 12 (63) 0 .001
IgG4-related sclerosing cholangitis 6 (31.5) 0 ns
Perisplenitis 1 (5) 0 ns
Lymphadenopathy 3 (16) 0 ns
Sialoadenitis 1 (5) 0 ns
Tubulointerstitial nephritis 1 (5) 0 ns
Lung disease 2 (10.5) 0 ns
Xerophthalmia 3 (16) 0 ns
Other autoimmune disease (%) 8 (42) 3 (30) ns
Sarcoidosis 0 1 (10) ns
Raynaud’s phenomenon 2 (10.5) 0 ns
Polymyalgia rheumatica 4 (21) 0 ns
Scleroderma 1 (5) 0 ns
Arteritis temporalis 1 (5) 0 ns
Muscular dystrophy, unknown genesis 1 (5) 0 ns
Sjögren syndrome 1 (5) 0 ns
Hypothyroidism (unspeciﬁed) 2 (10.5) 0 ns
Ulcerative colitis 0 3 (30) .03
Malignancy (%) 6 (31.5) 2 (20) ns
Type of malignancy Appendiceal mucinous neoplasm, testicular cancer,
malignant melanoma, colorectal cancer, chronic
myelomonocytic leukemia, urinary bladder cancer
Breast cancer, renal cell carcinoma
ns=not signiﬁcant.
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analyses. For comparison, a ROC curve was also made for IgG
(Fig. 1A). The results for IgG4 and anti-PBP are shown in Fig. 1B–
D and Table 5. For IgG4, the recommended cut-off of 1.4g/L for
differentiating AIP from PC/ACP was conﬁrmed as appropriate
and used (Fig. 1B). For anti-PBP, a cutoff value of 38.3U was
selected (Fig. 1C). For differentiation between AIP type 1 and 2, a
lower cut-off point for IgG4 of 1.09 performed better (Fig. 1D).
The ROC curve for the sensitivity and speciﬁcity of IgG4 for
differentiation of type 1 AIP and PC is shown in Fig. 1E. The
frequencies of IgG4-positivity in AIP, type 1 AIP, type 2 AIP,
ACP, and PC dependent on different cut-off values are presented
in Table 6. The sensitivity and speciﬁcity of IgG4 dependent on
different cut-off values is shown in Table 7.
We performed analysis of ANCA in 17 out of 19 type 1 AIP
patients and in all type 2 AIP patients (data not shown). Samples
from the type 1 AIP patients were c-ANCA-negative in all cases,
whereas 30% of type 2 AIP samples were c-ANCA-positive
(P< .05). Besides c-ANCA and IgG4, no other serological marker
showed signiﬁcant difference between type 1 and type 2AIP.When
regarding type 1 AIP alone and comparing these patients to the
control groups, the sensitivityof IgG4 improved (Tables5and7).A
prevalence of AIP of 1.5% will result in a positive and negative
predictive value of 3.8% and 99%, respectively. When combining
the markers, the diagnostic performance did not improve.
4. Discussion
The aim of this study was to estimate the usefulness of a-PBP,
serum IgG, serum IgG4, a-LF, a-CA-II, ANA, and RF for the
differential diagnosis of AIP versus PC. Our data conﬁrm that an
Table 4
Serological ﬁndings in patients with type 1 and type 2 autoimmune pancreatitis (AIP), pancreatic cancer (PC), pancreatic neuroendocrine
neoplasm (P-NEN), and alcoholic chronic pancreatitis (ACP).
AIP PC AIP vs PC P-NEN ACP AIP vs ACP AIP, PC, ACP AIP-1 AIP-2 AIP-1 vs AIP-2
n=29 n=17 P
∗
n=12 n=41 P
∗
P# n=19 n=10 P
∗
IgG, g/L Mean 11.3 10.3 .67 11.6 10.3 .93 .55 12.1 9.8 .35
SD 6 3.5 2.9 2.8 6.9 3.4
IgG4, g/L Mean 4.2 0.7 .04 0.72 0.9 .04 .01 6 1 <.01
SD 8.5 0.8 0.65 0.8 10.1 1.4
a-CA-II, U/mL Mean 40 128 .18 61.8 83 .79 .28 41 36 .65
SD 45 215 66.5 222 49 39
a-PBP, U/mL Mean 57 73 .10 80.5 97 <.01 .01 64 45 .17
SD 48 39 67.7 60 49 46
ANA Positive (%) 45 55 .43£ 50 56 .35£ .56£ 42 50 .69
a-LF, U/mL N 12 4 7 11
Mean 0.89 0.9 0.76 .04 .22
SD 0.09 0.2 0.24
RF, U/mL N 14 5 7 19
Cut-off ≥15
positive (%)
0 60 14 21 .07x
a-CA-II= anti-carbonic anhydrase II, a-LF= anti-lactoferrin, ANA= anti-nuclear antibodies, a-PBP=anti-plasminogen binding peptide, IgG= immunoglobulin G, IgG4= immunoglobulin G4, RF= rheumatoid
factor.
∗
Mann–Whitney U test.
# ANOVA test.
x Fisher exact test.
£ Chi2-test.
Table 5
Sensitivity and speciﬁcity of IgG4 and anti-PBP in differentiating autoimmune pancreatitis (AIP) from pancreatic cancer (PC), alcoholic
chronic pancreatitis (ACP) and PC/ACP, and AIP Type 1 from PC/ACP and AIP Type 2.
AIP and PC/ACP
Cut-off Sensitivity CI Speciﬁcity CI
IgG4 ≥1.4 45% 26–64% 84% 73–93%
a-PBP <38.3 45% 26–64% 81% 69–90%
AIP Type 1 and PC/ACP
IgG4 ≥1.4 58% 33–79% 84% 73–93%
a-PBP <38.3 32% 26–64% 81% 69–90%
AIP and PC
IgG4 ≥1.4 45% 26–64% 88% 64–99%
a-PBP <38.3 45% 26–64% 71% 44–90%
AIP and ACP
IgG4 ≥1.4 45% 26–64% 83% 64–94%
a-PBP <38.3 45% 26–64% 85% 71–94%
AIP Type 1 and Type 2
IgG4 ≥1.09 68% 43–87% 80% 44–97%
IgG4= Immunoglobulin G4, a-PBP= anti-plasminogen binding peptide. Because there were made no comparisons, no statistical tests were used. Instead, 95% conﬁdence intervals (CI) are given.
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increased level of serum IgG4 is an independent predictor of type
1 AIP, although the sensitivity was lower than in East-Asian
patients.[23–28] We also found that higher concentrations of
serum IgG4 correlated with a higher probability of type 1 AIP.
However, also a few PC andACP patients showed elevated serum
IgG4 levels, particularly in the range between once and twice the
upper limit of normal, in accordance with published studies.[23,24]
We were unable to conﬁrm the reported utility of a high a-PBP
value as a marker of AIP, in accord with recent studies from The
Netherlands and the UK.[29,30]
In the present study, we found a higher number of AIP patients
with a low a-PBP than PC patients, when using a cut-off of 38.3
U, but the sensitivity and speciﬁcity was very low. Moreover, as
also at least some healthy patients will show low values, it is
unlikely that this ﬁnding can be of diagnostic value. Hence, our
data cannot conﬁrm the report from Frulloni et al[13] who found
signiﬁcantly raised a-PBP in AIP patients, with both sensitivity
and speciﬁcity >90% using 110 PC patients as a control group.
Our results differ to such an extent, that it must be considered
whether the same molecule has been measured. It would be
Figure 1. Sensitivity and speciﬁcity for differentiating autoimmune pancreatitis (AIP) from pancreatic cancer (PC)/alcoholic chronic pancreatitis (ACP) of (A) IgG, (B)
IgG4, and (C) anti-plasminogen-binding peptide (anti-PBP). Sensitivity and speciﬁcity of IgG4 for differentiating (D) type 1 AIP from type 2 AIP, and (E) type 1 AIP from
PC. Receiver operating characteristic (ROC) curves. AUC=area under the curve, CI=conﬁdence interval, IgG= immunoglobulin G, IgG4= immunoglobulin G4.
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interesting to identify the proportion of our enrolled patients who
are Helicobacter pylori (HP) positive, since this condition is
suspected of triggering the development of AIP and elevated PBP-
values, but unfortunately, we did not evaluate this parameter in
our patients.[31,32] It is also possible that the ratio of HP-positive
patients was lower in our AIP cohort than in our PC and ACP
cohorts, which may have contributed to the slightly higher
number of AIP patients with low a-PBP values, as compared with
the PC and ACP patients. The mean a-PBP values were higher in
ACP than in PC. Again, it is possible that differences in HP-
positivity may in part have contributed to these ﬁndings. The
prevalence of HP-positive patients is likely to be higher in the
original study on a-PBP, but this should also apply to their
control groups.[13] A possible limitation of our study is that most
patients had already received steroid treatment at the time of
measurement of a-PBP, and also differences in the methods used
for analysis may inﬂuence the results. Our measurement of a-PBP
IgG antibodies was based on the method described in the original
report, using the bacterial PB peptide of the AKEERRY sequence,
similar to Buijs et al,[29] but without a biotinylated anchor
sequence.[13] We used a traditional solid-phase immunoassay
format (ELISA) with direct antigen coating and enzyme-
generated colorimetric-based detection instead of the time-
resolved ﬂuorescence methodology used in the original publica-
tion.[13]
As expected and in accordance with earlier studies, we found a
signiﬁcant difference regarding mean serum IgG4 concentrations
between AIP, PC, and ACP patients.[12,14,17,23–28] 45% of AIP,
58% of type 1 AIP, and 12% of PC patients had serum IgG4
values above the cut-off of 1.4g/L. In comparison, Chang et al[12]
reported IgG4 levels above this cut-off in 64.8% of AIP and 20%
of PC patients. This low proportion of serum IgG4 elevation in
the present series is probably due to that Chang reported of
South-East Asian patients, where there is a higher rate of type 1
AIP and a lower rate of type 2 AIP, in contrast to Europe
including Denmark.[10,12,25,26] In a recent study from the United
States, elevated serum IgG4was found in 66%of AIP and 10%of
PC.[14] When using a cut-off of 1.4g/L, the sensitivity and
speciﬁcity of serum IgG4 in differentiating AIP from PC were
45% and 88% in our study. In a recent meta-analysis, the
respective values were 73% and 93%.[16] However, again, the
proportion of type 1 AIP patients in the meta-analysis was
probably higher than in our study.[16] However, even when
taking this into account, only 58% of our type 1 AIP patients had
IgG4 levels above the common cut-off of 1.4g/L. Interestingly,
this value rose to 68% when using a cut-off of 1.09g/L, without
increasing the number of IgG4-positive PC patients (Table 6). It is
important to note the overlap in concentrations between the
groups, resulting in 6% of PC patients and 5% ACP patients
presenting with serum IgG4 values above twice upper limit of
normal (2.8g/L), in accordance with previous ﬁndings.[12,15,24,33]
We found elevated serum IgG4 levels (>1.25g/L) in two type 2
AIP patients (20%), which is consistent with previous ﬁnd-
ings.[34] In our study, a cut-off for IgG at 13.5g/L had a sensitivity
of 24% and a speciﬁcity of 82.7% for differentiating AIP from
PC. In a recent meta-analysis, the respective values were 51% and
94%.[16]
Since there is no established normal range for the concentration
of anti-CA-II, we only considered the differences in concen-
trations between the groups. Anti-CA-II was higher in the PC and
ACP groups when compared with AIP, but the difference was not
statistically signiﬁcant. Okazaki et al[17] found elevation of anti-
CA-II in 59% of AIP (n=17) but in none of the ACP patients (n=
17). In the same year, another Japanese study reported elevation
in 33% of AIP (n=6) and none of ACP (n=16).[35] Aparisi
et al[36], on the other hand, reported anti-CA-II elevation in
Spanish patients with ACP (10.5%) as well as in AIP (27.8%),
more in line with our data. However, another Japanese group
reported elevated anti-CA-II in 88.9% of AIP (n=9) and 45.8%
of ACP (n=24), and in a recent Spanish study, similarly in 83%
of AIP (n=12), 50% of idiopathic chronic pancreatitis (n=26),
29% of PC, and 9% of chronic pancreatitis (n=23).[15,37] In an
Table 6
Frequency of IgG4-positivity in autoimmune pancreatitis (AIP), type 1 AIP, type 2 AIP, pancreatic cancer (PC), and alcoholic chronic
pancreatitis (ACP), dependent on the selected cut-off value for serum IgG4.
IgG4 cut-off AIP AIP Type 1 AIP Type 2 PC ACP
n 29 19 10 17 41
1.09g/L 52% 68% 20% 12% 29%
1.25g/L 45% 58% 20% 12% 22%
1.40g/L 45% 58% 20% 12% 17%
2.80g/L 28% 37% 10% 6% 5%
IgG4= Immunoglobulin G4.
Table 7
Sensitivity and speciﬁcity at various cut-off values of IgG4 for the differentiation of autoimmune pancreatitis (AIP) and type 1 AIP from
pancreatic cancer (PC).
AIP versus PC AIP type 1 versus PC
Cut-off value Sensitivity CI Speciﬁcity CI Sensitivity CI Speciﬁcity CI
1.09g/L 52% 33–71% 88% 64–94% 68% 43–87% 88% 64–99%
1.25g/L 45% 26–64% 88% 64–99% 58% 33–80% 88% 64–99%
1.4g/L 45% 26–64% 88% 64–99% 58% 33–80% 88% 64–99%
2.8g/L 28% 13–47% 94% 71–100% 37% 16–61% 94% 71–100%
3.6g/L 28% 13–47% 100% 80–100% 37% 16–61% 100% 80–100%
Because there were made no comparisons, no statistical tests were used. Instead, 95% conﬁdence intervals (CI) are given.
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unselected cohort of CP patients back in 2000, Frulloni et al[38]
reported a-CA-II elevation in 26%. Hence, the exact role of this
marker for the differentiation of AIP from PC remains to be
elucidated and should probably be performed in the frame of a
large, international multicenter study to eliminate possible
methodological differences. Because initial studies on a few
AIP patients indicated usefulness of rheumatoid factor (RF) and
a-lactoferrin (a-LF) antibodies in AIP, we also included these
markers in our survey.[17,35] RF were detected more frequently in
PC patients compared with AIP, but this may be due to the higher
age of the PC patients. 45% of our AIP patients were ANA-
positive. By comparison, others have found ANA-positivity in
AIP ranging from 20.3% to 76.4%.[17,35,39] In the present study,
c-ANCA was elevated in 30% of type 2 AIP and none of type 1
AIP. Hence, ANCA may be a potential marker that can
contribute to the differentiation of type 1 from type 2 AIP, but
larger studies are needed to evaluate this aspect.
The inconsistency of the markers tested in our study and in the
various studies cited is remarkable and may be due to: different
populations studied, as the IgG4-positive type 1 AIP is more
common in Asia than in the West, differences in biochemical
methods and cut-off values, lack of distinction between AIP
subtypes and lack of an appropriate control group, publication
bias, where negative results are less likely to be published,
differences in treatment status of the included patients (i.e., before
or after immunosuppressive treatment), and differences in
diagnostic criteria and identiﬁcation of patients. Our study has
several limitations and strengths. The large majority of AIP cases
were supported by pancreatic histology (24 of 29 cases), which
should be considered a strength as many other serological studies
are based on serum IgG4 as one of the diagnostic criteria, which
may introduce selection bias and may contribute to some of the
differences between our study and other studies. A weakness of
our study is that serology might be affected by medical treatment,
and most of our patients had started steroid treatment at time of
blood sampling, due to the retrospective nature of this study.
However, Ghazale et al[24] demonstrated that the exclusion of
treated patients did not signiﬁcantly alter the sensitivity and
speciﬁcity of the serological markers. Unfortunately, only 17 PC
patients were included in this study, which is a low number
of patients, particularly compared with the number of included
patients with AIP (n=29), which is a rare disease. The low
number of PC patients included in this study may very well have
inﬂuenced the results, and in particular the calculations regarding
the statistical signiﬁcance. Finally, a promising marker for the
diagnosis of AIP is anti-amylase-a2A, with reported sensitivities
and speciﬁcities ranging from 76%–88% and 78%–99%,
respectively.[40,41] Unfortunately, we were not able to include
this marker in the present study.
In conclusion, the only marker for which we found a
statistically signiﬁcant difference in mean values between AIP
and PC was IgG4. However, the value of serum IgG4 for the
distinction of AIP from PC and ACPwas limited, probably in part
due to the relatively high number of type 2 AIP patients in our
study. For differentiation of type 1 AIP and PC, IgG4 had a
sensitivity of 68% and a speciﬁcity of 88% when using a cut-off
of 1.09g/L. In accord with recent publications, our data do not
support a role of increased a-PBP for the diagnosis of AIP.
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